| 000 | 01606 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250514025055.0 | ||
| 264 | 0 | _c20020628 | |
| 008 | 200206s 0 0 eng d | ||
| 022 | _a0014-2972 | ||
| 024 | 7 |
_a10.1046/j.1365-2362.2002.0320s1079.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aStam, T C | |
| 245 | 0 | 0 |
_aRegulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. _h[electronic resource] |
| 260 |
_bEuropean journal of clinical investigation _cMar 2002 |
||
| 300 |
_a79-83 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 |
_aAcute-Phase Reaction _ximmunology |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aC-Reactive Protein _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFerritins _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInterferon alpha-2 |
| 650 | 0 | 4 |
_aInterferon-alpha _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPhospholipases A _xblood |
| 650 | 0 | 4 | _aPhospholipases A2 |
| 650 | 0 | 4 | _aRecombinant Proteins |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aStill's Disease, Adult-Onset _xblood |
| 700 | 1 | _aSwaak, A J G | |
| 700 | 1 | _aKruit, W H J | |
| 700 | 1 | _aEggermont, A M M | |
| 773 | 0 |
_tEuropean journal of clinical investigation _gvol. 32 Suppl 1 _gp. 79-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1046/j.1365-2362.2002.0320s1079.x _zAvailable from publisher's website |
| 999 |
_c11793111 _d11793111 |
||